# ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Canonical URL: https://biopharmsignal.com/news/IBRX/immunitybio-reports-net-product-revenue-increased-nearly-2-7-times-year-over-year-to-record-44-million-in-q1-2026-and-381-million-in-cash-and-marketable-securities
Ticker: IBRX
Company: ImmunityBio
Source: ImmunityBio
Published: 2026-04-09 11:30 EST
Original Source URL: https://ir.immunitybio.com
## Summary

Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA ® by U.S.

## Article Body
Preliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA ® by U.S.
## Recent Company News
- 2026-06-01 17:51 EST — [ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026](https://biopharmsignal.com/news/IBRX/immunitybio-presents-new-clinical-and-comparative-data-across-lung-and-bladder-cancer-at-asco-2026) — Source: ImmunityBio
- 2026-05-22 11:30 EST — [ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation](https://biopharmsignal.com/news/IBRX/immunitybio-highlights-patient-survey-data-at-ispor-2026-showing-majority-of-uk-adults-living-with-nmibc-favor-bladder-preservation) — Source: ImmunityBio
- 2026-05-22 11:30 EST — [ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS](https://biopharmsignal.com/news/IBRX/immunitybio-presents-health-economic-analysis-at-ispor-2026-showing-anktivar-plus-bcg-delivers-lower-cost-per-sustained-complete-response-versus-tar-200-in-bcg-unresponsive-nmibc-cis) — Source: ImmunityBio
- 2026-05-20 00:30 EST — [ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027](https://biopharmsignal.com/news/IBRX/immunitybio-announces-fda-acceptance-of-supplemental-bla-for-anktivar-plus-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-papillary-disease-pdufa-date-set-for-january-6-2027) — Source: ImmunityBio
- 2026-05-19 11:30 EST — [ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026](https://biopharmsignal.com/news/IBRX/immunitybio-presents-favorable-comparative-effectiveness-data-in-complete-response-rates-of-nai-bcg-versus-nadofaragene-and-tar-200-at-aua-2026) — Source: ImmunityBio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)